Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05134350 · ClinicalTrials.gov registry record · Phase 1

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Loxo Oncology.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT05134350 is a Phase 1 study of Healthy Volunteers that has completed, run by Loxo Oncology. The registered enrollment target is 10 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05134350, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Loxo Oncology.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.

Conditions Studied

Interventions

  • DRUG Omeprazole
  • DRUG LOXO-305

Study Locations (1)

Florida

  • Covance Clinical Research Unit - Daytona Beach

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-02-06
Est. Completion 2020-03-23
Phase Phase 1

Sponsor

Loxo Oncology

14 total trials

What the Registry Record Tells You About NCT05134350

The ClinicalTrials.gov registry entry for NCT05134350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The listed sponsor is Loxo Oncology, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Omeprazole is the first listed.

NCT05134350 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05134350 about?

NCT05134350 is a clinical study titled "Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants". The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.

What is the current status of trial NCT05134350?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-02-06. Estimated completion is 2020-03-23.

What conditions does trial NCT05134350 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT05134350?

The interventions under investigation include: Omeprazole (DRUG), LOXO-305 (DRUG).

Who is sponsoring clinical trial NCT05134350?

This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05134350 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.